Drug Trial Radar · NCT05642325
Vamikibart in Participants With Uveitic Macular Edema
Last checked: Nov 20, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
256
Actual
Start
Mar 23, 2023
Primary completion
May 7, 2025
Study completion Dec 24, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.
Conditions
- Uveitic Macular Edema
Interventions
VamikibartDrug
Participants will receive vamikibart IVT injection
ShamOther
Participants will receive a sham procedure that mimics an IVT injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with ≥ 15 letter improvement from baseline in best-corrected visual acuity (BCVA) at Week 16Time frame: Week 16
Locations
94 sites in 19 countries. Site status is shown where the registry gives one.
Associated Retina Consultants
Phoenix, Arizona
Barnet Dulaney Perkins Eye Center
Sun City, Arizona
Retina Consultants of Orange County
Fullerton, California
Northern California Retina Vitreous Associates
Mountain View, California
California Eye Specialists Medical group Inc.
Pasadena, California
Retina Consultants of Southern California
Redlands, California
Kaiser Permanente Riverside Medical Center
Riverside, California
University of California, Davis, Eye Center
Sacramento, California
Retinal Consultants Med Group
Sacramento, California
Advanced Research
Deerfield Beach, Florida
Retina Group of Florida
Fort Lauderdale, Florida
University Retina and Macula Associates, PC
Oak Forest, Illinois
Cumberland Valley Retina PC
Hagerstown, Maryland
University of Michigan, Kellogg Eye Center
Ann Arbor, Michigan
Duke Eye Center
Durham, North Carolina
Cleveland Clinic
Cleveland, Ohio
Erie Retina Research
Erie, Pennsylvania
Mid Atlantic Retina
Philadelphia, Pennsylvania
Retina Research Institute of Texas
Abilene, Texas
Retina Consultants of Texas
Bellaire, Texas
Retina Consultants of Texas
Katy, Texas
Retina Group of Washington
Fairfax, Virginia
University of Wisconsin
Madison, Wisconsin
Centro Privado de Ojos
Ciudad Autonoma Buenos Aires, Argentina
Buenos Aires Mácula
Ciudad Autonoma Buenos Aires, Argentina
Consultorios Medicos Oftalmológicos
Ciudad Autonoma Buenos Aires, Argentina
Oftalmologia Global
Rosario, Argentina
Organizacion Medica de Investigacion
San Nicolás, Argentina
Sydney Eye Hospital
Sydney, New South Wales, Australia
Centre For Eye Research Australia
East Melbourne, Victoria, Australia
Eye Surgery Associates
Malvern, Victoria, Australia
Retina Specialists Victoria
Rowville, Victoria, Australia
The Lions Eye Institute
Nedlands, Western Australia, Australia
Peking Union Medical College Hospital
Beijing, China
Beijing Tongren Hospital
Beijing, China
The First Affiliated Hospital, Chongqing Medical University
Chongqing, China
General Teaching Hospital Prague
Prague, Czechia
CHU Nantes - Hotel Dieu
Nantes, France
Hopital Lariboisiere
Paris, France
Hôpital COCHIN
Paris, France
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.